- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
FDA grants Orphan Drug Designation to IONIS-HTTRx
5 January 2016 • Author: Victoria White
The US Food and Drug Administration has granted Orphan Drug Designation for IONIS-HTTRx for the treatment of Huntington’s disease.
IONIS-HTTRx is a Gen. 2.0+ antisense drug. It is the first therapy to enter clinical development that is designed to directly target the cause of the disease by reducing the production of the protein responsible. In Huntington’s disease, the gene that encodes for the HTT protein contains a trinucleotide sequence that is repeated in the gene more than 36 times. The resulting HTT protein is toxic and gradually damages neurons in the brain.
IONIS-HTTRx has also been granted orphan drug designation by the European Medicines Agency for the treatment of patients with HD.
IONIS-HTTRx is the first therapy designed to treat the underlying cause of the disease
“Huntington’s disease is a rare genetic neurological disease in which patients experience deterioration of both mental abilities and physical control. Although the toxic protein produced from the huntingtin (HTT) gene in Huntington’s disease patients has been a target of interest for many years, IONIS-HTTRx is the first therapy to enter clinical development that is designed to treat the underlying cause of this fatal disease. The granting of Orphan Drug Designation in both the US and Europe highlights the significant need for a drug that could transform the treatment of Huntington’s disease,” said C. Frank Bennett, Ph.D., senior vice president of research at Ionis Pharmaceuticals.
Orphan drug designation entitles seven years of market exclusivity in the United States if market approval is granted for IONIS-HTTRx for the treatment of patients with Huntington’s disease. Additional incentives include tax credits related to clinical trial expenses, an exemption from the FDA-user fee, and FDA assistance in clinical trial design.
Ionis Pharmaceuticals and Roche are collaborating on the development of the treatment. To date, Ionis has earned $52 million in upfront and milestone payments from its relationship with Roche and is eligible to earn additional milestone payments as the drug progresses in development, as well as royalties on sales of IONIS-HTTRx if it is commercialised. Roche has the option to license IONIS-HTTRx from Ionis through the completion of the Phase 1/2a study.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics